TrialVaccine2021
The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
Jing Pu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this paperpooled ittrialcites it